• Find people
• Intranet

News

18/06/2024 - Institutional news

Hospital del Mar Participates in Two Studies Presented at ASCO that Change the Approach for Certain Lung Cancer Patients

These are two international clinical trials, LAURA and ADRIATIC, which confirm the positive effect of consolidation with systemic therapies following the combination of chemotherapy in two patient populations.

Hospital del Mar is one of the centers that participated in the international studies LAURA and ADRIATIC, presented at the American Society of Clinical Oncology (ASCO) conference held in Chicago, United States, from May 30 to June 3. The two trials were presented at two of the five plenary sessions of the conference and will change the standard of treatment for two types of lung cancer. Dr. Edurne Arriola, head of the lung cancer section of the Oncology Service, highlighted: "At Hospital del Mar, we participate in highly relevant clinical trials that are changing the approach for patients with this pathology."

Dr. Edurne Arriola

The LAURA Study

This study analyzed the ability of the combination of radiotherapy and chemotherapy with osimertinib, a drug that targets certain mutations in the EGFR gene, compared to the current standard, radiotherapy and chemotherapy, in patients with unresectable stage III non-small cell lung cancer with mutated growth factor receptor (EGFRm). Hospital del Mar was one of the centers participating in the trial, which showed that 65% of patients treated with osimertinib were progression-free after two years, compared to 13% of those who received placebo.

The effect was positive across all patient subgroups, with a response rate of 57% compared to 33% in the placebo-treated group. This makes this combination the new standard of treatment for these patients.

ADRIATIC

The same applies to the results obtained from the ADRIATIC study, which compared the combination of chemotherapy and radiotherapy with durvalumab immunotherapy to the usual approach, chemotherapy and radiotherapy, in a group of patients with limited-stage small cell lung cancer. A pathology where there have been no therapeutic advances in recent years.

In this case, the three-year overall survival was 56.5% in participants treated with the new combination, compared to 47.2% in those who received placebo. Additionally, 46.2% were progression-free compared to 34.2%. This treatment will also become the standard in the near future.

More news